Prosperico Ventures

Cytocares is a research and development company specializing in the creation of innovative macromolecule drugs for tumor immunotherapy. The company focuses on developing novel medications aimed at enhancing tumor immunity, specifically targeting both hematological and solid tumors. By leveraging advanced drug design techniques, Cytocares provides potential treatments that could significantly improve patient outcomes in the fight against various forms of cancer.

Jiaohong Biology specializes in molecular diagnostic technology, focusing on the development and application of clinical diagnostic kits and automated diagnostic equipment. The company offers services that promote advancements in precise tumor diagnosis, nucleic acid detection for epidemic viruses, as well as for animal and plant diseases. Additionally, Jiaohong Biology addresses food safety concerns through its diagnostic solutions. Its innovative products aim to provide accurate diagnostic capabilities, supporting various industries in enhancing their diagnostic processes.

KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.

Singlera Genomics Inc. specializes in genetic testing and molecular diagnostic technologies, focusing on non-invasive solutions for cancer screening and diagnosis. The company has developed a methylation detection platform that aids in early tumor detection and cancer prevention. Its offerings include tumor diagnosis, personalized treatment options, non-invasive prenatal diagnosis, and pre-implantation genetic screening, along with customized scientific research services. Founded in 2014 and based in La Jolla, California, Singlera also operates research and development centers in Shanghai, China, and is committed to advancing precision medicine to provide patients with early, accurate, and informative diagnoses.

Silexon is an AI-driven service provider focused on drug research and development. The company employs artificial intelligence to systematically integrate extensive drug-related data, enhancing the drug development process. Its offerings include comprehensive drug target panorama reports, personalized cell therapy solutions, and small molecule virtual screening. Additionally, Silexon specializes in AI technologies that support pharmaceutical companies through drug repositioning platforms and macro-molecular design models, providing essential technical and analytical support to researchers in the generic drug discovery process.

Its main business scope is medical device technology development and sales; biomedical technology development, technology transfer, technical consulting services; corporate marketing planning; market research; business information consulting; Management consulting services; self-operated and agent import and export business of various commodities and technologies.

InfiNovo, established in 2016, specializes in developing innovative healthcare solutions, particularly in the realm of chronic disease management. The company is dedicated to creating an accurate and affordable Continuous Glucose Monitoring (CGM) system for both Type 1 and Type 2 diabetes patients. InfiNovo's CGM aims to compete in the global market through its emphasis on accuracy, durability, and user-friendly design. Additionally, the company develops biosensors and application products that enhance diagnostic accuracy and treatment standards, providing technological tools that improve the management of chronic diseases.

Wolfman Medical Technology is a medical imaging equipment developer dedicated to medical imaging technology and brain

Xynomic Pharmaceuticals is dedicated to in-licensing, developing, and commercializing oncology drug candidates across China, the United States, and other global markets. The company's founders bring extensive experience from leading multinational biopharmaceutical firms, such as Schering, Eli Lilly, Merck, and Roche, where they held research and development roles. They also possess a proven track record of founding and successfully exiting biopharmaceutical ventures that bridge the US and China. Xynomic aims to establish a robust pipeline of clinical and pre-clinical stage oncology treatments, specifically targeting cancers that have high prevalence rates in these regions. By leveraging global resources, the company seeks to enhance the efficiency of drug development, both in terms of cost and time.

Singlera Genomics Inc. specializes in genetic testing and molecular diagnostic technologies, focusing on non-invasive solutions for cancer screening and diagnosis. The company has developed a methylation detection platform that aids in early tumor detection and cancer prevention. Its offerings include tumor diagnosis, personalized treatment options, non-invasive prenatal diagnosis, and pre-implantation genetic screening, along with customized scientific research services. Founded in 2014 and based in La Jolla, California, Singlera also operates research and development centers in Shanghai, China, and is committed to advancing precision medicine to provide patients with early, accurate, and informative diagnoses.

Fourier Intelligence is a Shanghai-based technology and design company that specializes in the development of exoskeleton robotic products and services aimed at rehabilitation and orthoses. The company offers advanced robotics technology, including upper-limb rehabilitation robotics and lower-limb exoskeletons, which assist individuals with disabilities in overcoming physical limitations, enabling them to stand and walk again. Its innovative products not only enhance the quality of life for users but also improve productivity by reducing fatigue and facilitating the transportation of heavy objects in various sectors. Fourier Intelligence is committed to advancing healthcare and rehabilitation through its pioneering technologies, empowering individuals to regain mobility and independence.

Chao Ju Ophthalmology Hospital, established in 1988 and based in China, specializes in ophthalmic treatments, particularly laser and refractive eye surgeries. With over 30 years of experience in the field, the institution has developed a strong technical foundation, employing more than 2,000 professionals, including professors, researchers, and senior physicians. Additionally, the hospital operates over 100 medical clinics staffed by clinical professors, allowing it to provide comprehensive eye care services.

U-Dental is a Chinese dental clinic chain that specializes in a wide range of oral care services, including dental implants, orthodontic treatment, root canal therapy, periodontal treatment, and cosmetic dentistry. The company aims to enhance the quality of dental care across China by providing a welcoming environment for patients. U-Dental maintains strong partnerships with various international dental brands, allowing it to offer advanced oral treatments that meet global standards. Through its comprehensive approach, U-Dental strives to improve overall patient experiences and outcomes in dental health.

Thoth Medical specializes in the development of medical wearables that incorporate advanced biomedical sensor technology. The company focuses on integrating various technologies, including wireless transmission, artificial intelligence algorithms, and cloud monitoring, to create devices that enhance clinical medical services. Thoth Medical aims to deliver precise, efficient, comfortable, and safe solutions for healthcare, ultimately improving patient care through innovative wearable technology.

KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.